Telomere Metabolism and Diagnostic Demonstration of Telomere Measurement in the Human Esophagus for Distinguishing Benign from Malignant Tissue by Tissue Quantitative Fluorescence in situ HybridizationKammori M.a-c · Izumiyama N.c · Nakamura K.c · Kurabayashi R.b, c · Kashio M.c, d · Aida J.c · Poon S.S.S.e · Kaminishi M.b
aDepartment of Breast, Tokyo Metropolitan Tama Cancer Detection Center, bDivision of Gastrointestinal Surgery, and Metabolic Care and Endocrinological Surgery, Department of Surgery, Graduate School of Medicine, University of Tokyo, cResearch Team for Geriatric Disease, Tokyo Metropolitan Institute of Gerontology, and dDivision of Breast and Endocrine Surgery, Department of Surgery, Nihon University, Tokyo, Japan; eTerry Fox Laboratory, British Columbia Cancer Research Center, Vancouver, B.C., Canada
Keywords: Anaphase/telophase bridgesChromosome instabilityEsophageal squamous cell carcinomaEsophageal stem cellTelomere shorteningTelomere/centromere intensity ratioTissue quantitative fluorescence in situ hybridization
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: We have developed a novel method for evaluating telomere length in four different cell types in non-cancerous and cancerous mucosal tissue from 15 cases of squamous cell carcinoma of the esophagus using tissue quantitative fluorescence in situ hybridization (Q-FISH). We hypothesized that the very rapid cell proliferation observed in esophageal squamous cell carcinomas might accelerate the telomere shortening and chromosomal instability associated with carcinogenesis. Methods: Tissue Q-FISH and the telomere to centromere intensity ratio (TCR) were used to compare telomere shortening in tissue sections taken from esophageal squamous cell carcinomas and adjacent non-cancerous esophageal tissues. Results: The peak percentage of TCR was <1 for esophageal squamous carcinoma cells and >1 for the non-cancerous esophageal cell types. Basal layer cells had the longest telomeres in comparison with prickle, cancer, and stromal cells, and strongly expressed hTERT, cytokeratin 14 and CD49f, but not MIB-1. Conclusion: These results suggest the presence of stem cells in the basal layer of the esophagus. Esophageal squamous cell carcinomas also display anaphase bridges, evidencing chromosomal instability.In conclusion, our TCR method can be used to distinguish between benign and malignant tissue in esophageal lesions. In order to apply this approach clinically to individual cases, further studies are in progress.
© 2006 S. Karger AG, Basel
- Blasco MA: Telomerase beyond telomeres. Nat Rev Cancer 2002;2:627–633.
- Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA: Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641–645.
- Gisselesson D, Jonson T, Petersen A, Strombeck B, Dal Cin P, Hoglund M, Mitelman F, Mertens F, Mandahl N: Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA 2001;98:12683–12688.
- Greider CW, Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405–413.
- Biessmann H, Mason JM: Telomere maintenance without telomerase. Chromosoma 1997;106:63–69.
- Colgin LM, Reddel RR: Telomere maintenance mechanisms and cellular immortalization. Curr Opin Genet Dev 1999;9:97–103.
- Harley CB, Villeponteau B: Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 1995;5:249–255.
- de Lange T: Telomeres and senescence: ending the debate. Science 1998;279:334–335.
- DePinho RA: The age of cancer. Nature 2000;408:248–254.
- Seery JP: Stem cells of the oesophageal epithelium. J Cell Sci 2002;115:1783–1789.
- O’Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, Emond MJ, Gollahon KA, Moskovitz AH, Crispin DA, Potter JD, Rabinovitch PS: Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002;32:280–284.
- Meeker AK, Hicks JL, Gabrielson E, Strauss WM, De Marzo AM, Argani P: Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 2004;164:925–935.
- Kuniyasu H, Kitadai Y, Mieno H: Helicobacter pylori infection is closely associated with telomere reduction in gastric mucosa. Oncology 2003;65:275–282.
- Finley JC, Reid BJ, Odze RD, Sanchez CA, Galipeau P, Li X, Self SG, Gollahon KA, Blount PL, Rabinovitch PS: Chromosomal instability in Barrett’s esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev 2006;15:1451–1457.
Hamilton SR, Aaltonen L: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive. Lyon, IARC Press, 2000, pp 17–19.
- Kammori M, Izumiyama N, Hashimoto M, Nakamura K, Okano T, Kurabayashi R, Hiki N, Honma N, Ogawa T, Kaminishi M, Takubo K: Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy. Int J Oncol 2005;27:1257–1264.
O’Sullivan JN, Finley JC, Risques RA, Shen WT, Gollahon KA, Moskovitz AH, Gryaznov S, Harley CB, Rabinovitch PS: Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms. Cytometry 2004;58:120–131.
- Jaras M, Edqvist A, Rebetz J, Salford LG, Widegren B, Fan X: Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression. Blood 2006;108:1084–1091.
- Mandard AM, Hainaut P, Hollstein M: Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutation Res 2000;462:335–342.
- Watt FM, Hogan BL: Out of Eden: stem cells and their niches. Science 2000;287:1427–1430.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.